NCT02171832View on ClinicalTrials.gov

Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

December 31, 2009

Conditions
HealthyLiver Diseases
Interventions
DRUG

BI 1744 CL, low dose

DRUG

BI 1744 CL, high dose

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02171832 - Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function | Biotech Hunter | Biotech Hunter